Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

UROGASTRONE

STATEMENT OF HAZARDOUS NATURE

Not considered a hazardous substance according to OSHA 29 CFR 1910.1200.

NFPA

PRODUCT USE

Growth factor involved in the repair of tissue following inflammation. Stimulates cardiac
adenylate cyclase through a GTP- binding protein. An inhibitory factor of gastric
secretion derived form human urine. Proposed for use in the treatment of duodenal and
gastric ulcer and related disorders. Two closely related water- soluble polypeptides,
beta- and gamma- urogastrone isolated from male and female urine were found to consist of
52 amino- acid residues in the same sequence with the beta- form possessing an additional
terminal arginine.

SYNONYMS

"epidermal cell growth factor", "gastrone, uro-", "Anthelone U", EGF, Kutrol,
Uroanthelone, Uroenterone, Urogastron, "gastro-intestinal agent."

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

None

EMERGENCY OVERVIEW

RISK

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Although ingestion is not thought to produce harmful effects, the material may still be damaging to the health of the individual following ingestion, especially where pre-  existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality (death) rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.  Considered an unlikely route of entry in commercial/industrial environments.  

EYE

  Although the material is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn).  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  

INHALED

  The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.  Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.  

CHRONIC HEALTH EFFECTS

  Principal routes of exposure are usually by skin contact/absorption and inhalation of generated dust.  No human exposure data available. For this reason health effects described are based on experience with chemically related materials.  As with any chemical product, contact with unprotected bare skin; inhalation of vapor, mist or dust in work place atmosphere; or ingestion in any form, should be avoided by observing good occupational work practice.